{"id":"W2914258217","doi":"10.1002/cncr.31999","title":"Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Servier; Astellas Pharma; MacroGenics; Agios Pharmaceuticals; Regeneron Pharmaceuticals; EMD Serono; Mersana Therapeutics; Karyopharm Therapeutics; PTC Therapeutics; Sanofi; GlaxoSmithKline; Amgen; Pfizer; MorphoSys; Celgene; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Immunotherapy; Internal medicine; Clinical trial; Oncology; Response Evaluation Criteria in Solid Tumors; Cancer; Disease; Adverse effect; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003211694,0.0001262797,0.0003725194,0.0003582506,0.0002580039,0.0006218502,0.0002822447,0.0002550696,0.001169617],"category_scores_gemma":[0.004673697,0.0001292497,0.0002955812,0.0007408864,0.0002358741,0.0004705096,0.0003417566,0.0005169984,0.0001152755],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003180256,"about_ca_system_score_gemma":0.00039188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000168775,"about_ca_topic_score_gemma":0.0004229018,"domain_scores_codex":[0.9984207,0.0008235132,0.0002578783,0.0001709436,0.000232367,0.00009464428],"domain_scores_gemma":[0.9912434,0.00326354,0.004209819,0.000211238,0.0004258444,0.0006462922],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001084084,0.00006015586,0.9904284,0.00006834694,0.00006343252,0.0001520692,0.00004668486,0.000148779,0.0006047935,0.00002453493,0.0001680802,0.007150639],"study_design_scores_gemma":[0.0001333568,0.0009698925,0.9952061,0.00004586658,0.000101865,0.001503914,0.0000876952,0.0005208813,0.0004640903,0.00007270562,0.0008886295,0.00000497203],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971071,0.001955942,0.0001410008,0.00008912014,0.000005351672,0.00004233919,0.0001412762,0.000003164212,0.0005147207],"genre_scores_gemma":[0.9992262,0.0002647747,0.0001611099,0.00004868288,0.0000194484,0.00003271944,0.0001710635,0.000001529439,0.00007446353],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003211694,"threshold_uncertainty_score":0.01698524,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02489880989038091,"score_gpt":0.3612984301281122,"score_spread":0.3363996202377313,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}